Anemocyte
Anemocyte is an Italian Biotech Manufacturing Organization specializing in plasmid DNA and mRNA development and manufacturing for cell and gene therapy, vaccine, and viral vector clients across R&D to GMP grades.
- Company typePrivate
- Founded2017
- HeadquartersGerenzago, Italy
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Anemocyte does
Anemocyte S.r.l. is an Italian Biotech Manufacturing Organization (BMO) headquartered in Gerenzano, Italy, specializing in plasmid DNA (pDNA) and mRNA development and manufacturing for advanced therapy applications. The company produces nucleic acid starting materials across three quality grades (R&D under ISO 9001:2015, High Quality, and full GMP for EMA/FDA-regulated clinical and commercial use), with batch sizes ranging from 1mg to multigram scale. Its core technology platform includes the proprietary AMCAP™ mRNA capping technology and the AMClarity visual inspection division, which supplies defective reference sets and GMP qualification services to pharmaceutical and biotech clients. Manufacturing capacity comprises 500 sqm of dedicated production and QC space plus 800 sqm of cleanrooms added in a 2019 expansion.
Anemocyte serves cell and gene therapy developers, mRNA vaccine and therapy developers, viral vector manufacturers, and pharmaceutical CDMOs requiring process development support. Named customers include Genenta Science (pDNA and cell banks for Temferon™ immunotherapy in glioblastoma and renal cell carcinoma) and Altheia Science (Master Cell Banks and pDNA for autoimmune disease cell and gene therapy programs). The company generates revenue through quote-based, multi-year contract manufacturing agreements, supplemented by an e-commerce storefront at shop.anemocyte.com for off-the-shelf mRNA, pDNA, and IVT kits targeting smaller research customers.
The business is family-owned, debt-free, and structured as a Single Shareholder Private Limited-Liability Company (S.r.l.) under Italian law with €530,000 of fully paid share capital. In March 2025, Anemocyte opened Anemocyte Inc., a wholly-owned US subsidiary in Miami, Florida, appointing an Account Director to develop North American business. Distribution relies on direct enterprise sales, industry conference participation (ISCT, ASGCT, CPHI, BIO, TIDES, Advanced Therapies Week), and national pavilions at international events, with geographic coverage spanning Italy, Switzerland, Germany, Spain, Portugal, the United States, and Japan.
Anemocyte firmographics
Firmographics- Name
- Anemocyte
- Legal name
- Anemocyte S.r.l.
- Website
- https://anemocyte.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Anemocyte is an Italian Biotech Manufacturing Organization specializing in plasmid DNA and mRNA development and manufacturing for cell and gene therapy, vaccine, and viral vector clients across R&D to GMP grades.
- Ownership category
- akta.pro rank
Anemocyte industry classification
Industry- Product category
- Biotech Contract Manufacturing Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)
- akta.pro secondary industries
- mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
Keywords
Where Anemocyte is headquartered
LocationHeadquarters
- HQ city
- Gerenzago
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
Anemocyte business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Contract Manufacturing Services (pDNA): Plasmid DNA manufacturing services at R&D, High Quality, and GMP grade levels for viral vector production, cell therapies, gene therapies, and vaccine development. Pricing based on batch size (1mg to multigram) and quality grade requirements.
- Contract Manufacturing Services (mRNA): mRNA development and manufacturing services including template design, IVT, capping, purification, and formulation for therapeutic applications
- AMClarity Inspection Services: Visual inspection qualification services including custom defective reference sets and GMP consulting/training for pharmaceutical and biotech companies
- Related Services: Process development, cryopreservation, stability studies, and secondary packaging services supporting the core manufacturing offerings
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | R&D Grade pDNA - ISO 9001:2015 compliant for early-stage research |
| Unit Pricing | Multi-year contract | High-Quality (HQ) Grade pDNA - GMP guidelines with full traceability |
| Unit Pricing | Multi-year contract | GMP Grade pDNA - Strict regulatory standards for clinical/commercial |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
Anemocyte product offering
Product offeringCore offering
Anemocyte is a Biotech Manufacturing Organization (BMO) that develops and manufactures plasmid DNA (pDNA) and mRNA at R&D, High Quality, and GMP grades for biotech and pharmaceutical companies developing advanced therapies. The company delivers end-to-end services from process development and DNA template design through IVT, capping, purification, fill/finish, and cryopreservation, with proprietary AMCAP™ mRNA capping technology and AMClarity visual inspection solutions. Its customer base includes cell and gene therapy developers, mRNA vaccine developers, and viral vector manufacturers requiring reliable supply of nucleic acid starting materials.
Product overview
Anemocyte is a Biotech Manufacturing Organization (BMO) offering a portfolio of nucleic acid manufacturing solutions centered on two core technology platforms: Plasmid DNA (pDNA) and mRNA development and manufacturing. The portfolio includes the proprietary AMCAP™ capping technology and the AMClarity visual inspection division. Anemocyte provides end-to-end services from R&D to GMP manufacturing, with supporting services including cryopreservation, stability studies, secondary packaging, and process development. The company positions itself as the world's first BMO, offering flexible manufacturing capabilities across multiple quality grades (R&D, HQ, GMP) for plasmid DNA and mRNA products.
Differentiator
Problem solved
Functional benefit
Brands
- AMCAP™: mRNA capping technology platform - a smarter way to cap mRNA
- AMClarity
- AMClarity
Products and services
- Plasmid DNA (pDNA) Development and Manufacturing Contract manufacturing of plasmid DNA in three quality grades (R&D, High Quality, and GMP) for biotech and pharmaceutical companies developing viral vectors, cell therapies, gene therapies, and vaccines. Batch sizes range from 1mg to multigram with full regulatory documentation and Certificates of Analysis.
- mRNA Development and Manufacturing Contract manufacturing of mRNA for vaccines and advanced therapies, covering the full production workflow from DNA template design through in vitro transcription (IVT), capping, purification using membrane chromatography and monolithic columns, and final drug substance formulation.
- AMCAP™ Proprietary mRNA capping technology platform providing an approach to mRNA capping for enhanced stability and efficiency, integrated within Anemocyte's mRNA manufacturing offering for vaccine and therapeutic developers.
- AMClarity Specialized division providing precision-engineered defective reference standards and GMP qualification/training services for pharmaceutical and biotech companies' visual inspection processes.
- Cryopreservation and Storage Services Controlled storage and cryopreservation services with temperature options ranging from -80°C to ambient, including nitrogen cryopreservation, fully monitored with controlled access for cell banks, plasmid DNA, mRNA, and other biological materials.
- Stability Studies Customized stability studies tailored to client timelines and testing requirements, utilizing a panel of quality control assays for plasmid DNA, mRNA, and related biological products.
- Secondary Packaging Secondary packaging service providing anti-tampering boxes with sponge material protecting primary packages during shipping and preventing product shifting during delivery.
- Process Development Services Process optimization and development support across different production phases of plasmid DNA and mRNA manufacturing, including tech transfer activities between development and manufacturing stages.
Quantifiable outcome
- Facility expansion completed August 2019
- +2 more outcomes
Companies that use Anemocyte
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
Anemocyte technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Anemocyte partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Genenta SciencecoreExpanded strategic partnership to advance off-the-shelf LVV (Lentiviral Vector) Plasmid DNA technology platform. The partnership leverages Genenta's proprietary LVV Plasmid DNA platform to enhance Anemocyte's product offerings for advanced therapy programs across the industry.
- Altheia SciencecoreStrategic collaboration providing Master Cell Banks and plasmid DNA for viral vector manufacturing to support Altheia's cell and gene therapy pipeline for autoimmune diseases. The partnership emphasizes speed and precision in manufacturing with Anemocyte serving as a key strategic partner accelerating path toward clinical trials.
- Genenta SciencecoreStrategic collaboration encompassing manufacturing of critical starting materials including Cell Banks and Plasmids for viral vector production. The partnership supports Genenta's Temferon™ immunotherapy platform for Glioblastoma Multiforme and Renal Cell Carcinoma. Anemocyte provides high-quality pDNA that met Genenta's expectations for production of high-quality therapeutic products.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Anemocyte competitors and assessment
Company assessmentDirect peers
- Aldevron: Aldevron is a leading CDMO specializing in plasmid DNA, mRNA, and protein manufacturing for cell and gene therapy developers — Anemocyte's core capability set, with overlapping R&D-to-GMP grade offerings and a similar advanced-therapy customer base.
- Cobra Biologics (Charles River Laboratories): Cobra Biologics, now part of Charles River, provides plasmid DNA and viral vector manufacturing services for gene therapy and cell therapy developers — directly comparable in modality (pDNA/viral vectors) and customer profile to Anemocyte.
- Vibalogics: Vibalogics is a CDMO focused on viral vector manufacturing for gene therapies, supplying process development, GMP manufacturing, and analytical services — a closely matched peer serving overlapping advanced-therapy customers from European operations.
- Celonic Group: Celonic is a European CDMO offering GMP manufacturing for biologics, cell and gene therapies, and viral vectors — competing with Anemocyte for advanced-therapy customers seeking GMP-grade nucleic acid and viral vector production.
Emerging players
- Polyplus (Sartorius): Polyplus, now part of Sartorius, provides plasmid DNA, transfection reagents, and process services for gene therapy and vaccine manufacturing — closely comparable upstream-pDNA capability with overlapping customer applications.
- Quantoom Biosciences: Quantoom Biosciences is an mRNA CDMO offering end-to-end mRNA production and process development for vaccines and therapeutics — overlapping with Anemocyte's mRNA manufacturing platform on the nucleic acid modality.
Broad incumbents
- Lonza Group: Lonza is a global CDMO leader with cell and gene therapy manufacturing services including viral vectors and mRNA — a much larger, multi-site incumbent whose pDNA/mRNA offerings compete with Anemocyte for advanced-therapy programs at higher scale.
- Catalent (Novo Holdings): Catalent is a broad CDMO with biologics, cell therapy, and plasmid DNA capabilities — a global incumbent that competes with Anemocyte for nucleic acid manufacturing programs across clinical and commercial stages.
- Thermo Fisher Scientific (Patheon viral vector services): Thermo Fisher's pharma services division offers plasmid DNA, viral vector, and mRNA CDMO capabilities — a large diversified incumbent with overlapping services competing for advanced-therapy customers.
- GenScript ProBio: GenScript ProBio is a CDMO offering plasmid DNA, viral vector, and cell therapy manufacturing services with global capacity — competing in Anemocyte's core nucleic acid and gene therapy modalities from an Asian and US footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Anemocyte social profiles
Digital presenceAnemocyte compliance and trust
Trust signalCompliance4 records
Anemocyte financial estimates
Financial estimateRevenue estimate
Valuation estimate
Anemocyte leadership team
Management profileNumber of profiles
Profiles1 record
Anemocyte subsidiaries and ownership
Company hierarchySubsidiaries1 record
Anemocyte funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Anemocyte M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Anemocyte
What does Anemocyte do?
Anemocyte is a Biotech Manufacturing Organization (BMO) that develops and manufactures plasmid DNA (pDNA) and mRNA at R&D, High Quality, and GMP grades for biotech and pharmaceutical companies developing advanced therapies. The company delivers end-to-end services from process development and DNA template design through IVT, capping, purification, fill/finish, and cryopreservation, with proprietary AMCAP™ mRNA capping technology and AMClarity visual inspection solutions. Its customer base includes cell and gene therapy developers, mRNA vaccine developers, and viral vector manufacturers requiring reliable supply of nucleic acid starting materials.
Is Anemocyte a public or private company?
Anemocyte is a private company. It is classified as family owned and is currently operating.
When was Anemocyte founded?
Anemocyte was founded in 2017. It employs 11 to 50 people.
Where is Anemocyte based?
Anemocyte is headquartered in Gerenzago, Italy, in the Europe region.
How does Anemocyte make money?
Four revenue lines are on record. Contract Manufacturing Services (pDNA) is the primary driver. The others are contract Manufacturing Services (mRNA), AMClarity Inspection Services and related Services.
Who are Anemocyte's main competitors?
Direct peers on record are Aldevron, Cobra Biologics (Charles River Laboratories), Vibalogics and Celonic Group. Emerging players are Polyplus (Sartorius) and Quantoom Biosciences. Broad incumbents are Lonza Group, Catalent (Novo Holdings), Thermo Fisher Scientific (Patheon viral vector services) and GenScript ProBio.
Does Anemocyte have an API?
No public API is recorded for Anemocyte.
What industry is Anemocyte in?
Anemocyte's product category is Biotech Contract Manufacturing Services. Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO. Its NAICS code is 325414 and its SIC code is 2836.